HRP20191215T1 - Formulacije etanercepta stabilizirane ionima magnezija - Google Patents

Formulacije etanercepta stabilizirane ionima magnezija Download PDF

Info

Publication number
HRP20191215T1
HRP20191215T1 HRP20191215TT HRP20191215T HRP20191215T1 HR P20191215 T1 HRP20191215 T1 HR P20191215T1 HR P20191215T T HRP20191215T T HR P20191215TT HR P20191215 T HRP20191215 T HR P20191215T HR P20191215 T1 HRP20191215 T1 HR P20191215T1
Authority
HR
Croatia
Prior art keywords
composition
less
weight
etanercept
peak
Prior art date
Application number
HRP20191215TT
Other languages
English (en)
Croatian (hr)
Inventor
Mark Manning
Brian Murphy
Original Assignee
Coherus Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coherus Biosciences, Inc. filed Critical Coherus Biosciences, Inc.
Publication of HRP20191215T1 publication Critical patent/HRP20191215T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
HRP20191215TT 2011-10-18 2012-10-18 Formulacije etanercepta stabilizirane ionima magnezija HRP20191215T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161548518P 2011-10-18 2011-10-18
US201261669480P 2012-07-09 2012-07-09
PCT/US2012/060739 WO2013059406A1 (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with metal ions
EP12842352.2A EP2768525B1 (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with magnesium ions

Publications (1)

Publication Number Publication Date
HRP20191215T1 true HRP20191215T1 (hr) 2019-10-04

Family

ID=48136153

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191215TT HRP20191215T1 (hr) 2011-10-18 2012-10-18 Formulacije etanercepta stabilizirane ionima magnezija

Country Status (28)

Country Link
US (21) US9393305B2 (forum.php)
EP (6) EP2768525B1 (forum.php)
JP (6) JP6104922B2 (forum.php)
KR (7) KR20140091706A (forum.php)
CN (6) CN104011073B (forum.php)
AR (6) AR088381A1 (forum.php)
AU (6) AU2012326168B2 (forum.php)
BR (6) BR112014009087A2 (forum.php)
CA (6) CA2851635A1 (forum.php)
CY (1) CY1121843T1 (forum.php)
DK (1) DK2768525T3 (forum.php)
EA (6) EA025663B1 (forum.php)
ES (1) ES2734070T3 (forum.php)
HK (3) HK1200718A1 (forum.php)
HR (1) HRP20191215T1 (forum.php)
HU (1) HUE045624T2 (forum.php)
IL (6) IL231826A0 (forum.php)
IN (3) IN2014CN02591A (forum.php)
LT (1) LT2768525T (forum.php)
MX (7) MX2014004732A (forum.php)
PL (1) PL2768525T3 (forum.php)
PT (1) PT2768525T (forum.php)
RS (1) RS59179B1 (forum.php)
SG (6) SG11201401519RA (forum.php)
SI (1) SI2768525T1 (forum.php)
SM (1) SMT201900422T1 (forum.php)
TW (6) TW201325607A (forum.php)
WO (6) WO2013059412A1 (forum.php)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
HK1200718A1 (en) 2011-10-18 2015-08-14 科荣生生物科学公司 Etanercept formulations stabilized with sodium chloride
JP2015525762A (ja) * 2012-07-09 2015-09-07 コヒラス・バイオサイエンシズ・インコーポレイテッド エタネルセプトの安定な水性製剤
PE20150996A1 (es) 2012-09-11 2015-08-01 Coherus Biosciences Inc Etanercept correctamente plegado de alta pureza y excelente rendimiento
US20160106844A1 (en) * 2013-05-02 2016-04-21 Mabxience, S.A. Alternative formulations for tnfr: fc fusion polypeptides
WO2015056613A1 (ja) * 2013-10-15 2015-04-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 安定化されたポリペプチド水性製剤
SI3060229T1 (sl) * 2013-10-24 2021-11-30 Astrazeneca Ab Stabilne vodne formulacije protiteles
CN106061468B (zh) 2013-11-29 2020-10-02 阿雷斯贸易股份有限公司 包含TNFR和Fc区的融合蛋白的液体制剂
IS3008B (is) 2014-05-14 2018-12-15 Calor ehf Stöðgandi lausnir fyrir prótín og peptíð
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
WO2021108427A1 (en) * 2019-11-26 2021-06-03 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US20180200325A1 (en) * 2014-11-18 2018-07-19 Shionogi & Co., Ltd. Stabilized peptide composition
HK1244685A1 (zh) * 2014-12-22 2018-08-17 阿雷斯贸易股份有限公司 液体药物组合物
WO2016103034A1 (en) * 2014-12-23 2016-06-30 Drug Discovery Laboratory As Protein compositions and use thereof
IL253218B (en) * 2014-12-31 2022-08-01 Lg Chemical Ltd A method for preparing a tnfr–fc fusion protein containing a targeted content of unpurified components
CN104694355B (zh) * 2015-03-20 2016-09-28 吉林大学 葛根护肝保健酒及其制备方法
MX389818B (es) * 2015-08-13 2025-03-20 Landsteiner Scient S A De C V Composicion de estabilidad mejorada de etanercept.
JP5938762B1 (ja) * 2015-09-01 2016-06-22 日揮株式会社 マイクロカプセル製剤及びその製造方法
CN105748414A (zh) * 2016-03-02 2016-07-13 张光泉 抗感染米卡芬净冻干组合物及其制备方法
JPWO2017179683A1 (ja) * 2016-04-15 2019-02-21 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ミカファンギンの安定化された医薬組成物
WO2018075818A1 (en) * 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
WO2018080196A2 (ko) * 2016-10-28 2018-05-03 (주)셀트리온 안정한 약제학적 제제
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
MX2017013995A (es) * 2017-10-31 2019-05-01 Probiomed S A De C V Formulacion farmaceutica estable de una proteina de fusion.
RU2020121415A (ru) * 2017-11-30 2021-12-30 Био-Тера Солюшнз, Лтд. Жидкий препарат гуманизированного антитела для лечения заболеваний, опосредованных ил-6
CA3189025A1 (en) * 2017-12-22 2019-06-27 Samsung Bioepis Co., Ltd. Liquid composition comprising vegf antagonist
US11253569B2 (en) 2018-05-03 2022-02-22 Seattle Children's Hospital Methods of treating Kawasaki Disease
CN111228225B (zh) * 2018-11-28 2022-08-26 鲁南制药集团股份有限公司 一种重组人肿瘤坏死因子受体-Fc融合蛋白冻干制剂
GB201911461D0 (en) 2019-08-09 2019-09-25 Arecor Ltd Novel composition
AU2022223669A1 (en) 2021-02-17 2023-08-03 Arecor Limited Aqueous composition of an engineered protein construct comprising an fc domain
CN114788809B (zh) * 2022-01-25 2023-04-14 江苏广承药业有限公司 一种氯雷他定液体制剂

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
NZ256293A (en) 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US6677326B2 (en) * 1999-03-15 2004-01-13 Arakis, Ltd. Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
AU4363200A (en) 1999-04-19 2000-11-02 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders
MXPA02007683A (es) 2000-02-10 2002-12-13 American Home Prod Metodo para tratar o inhibir la lesion celular o muerte celular.
ES2644275T3 (es) 2000-08-11 2017-11-28 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen anticuerpos
US6936437B2 (en) * 2001-02-23 2005-08-30 Lucia Irene Gonzalez-Villasenor Methods and compositions for production of recombinant peptides
CA2476934C (en) * 2002-02-27 2009-06-16 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
BRPI0407649A (pt) * 2003-02-28 2006-02-21 Ares Trading Sa formulação lìquida de proteìnas de ligação do fator de necrose tumoral, processo de preparação de formulação lìquida de proteìnas de ligação do fator de necrose tumoral e forma de apresentação de formulação
EP1607103A1 (en) 2003-03-20 2005-12-21 Eisai Co., Ltd. Concomitant drug as therapeutic agent for inflammatory bowel disease
JP2007521315A (ja) 2003-08-01 2007-08-02 アムジェン インコーポレイテッド 結晶性腫瘍壊死因子レセプター２ポリペプチド
GEP20084560B (en) 2003-10-14 2008-12-10 Ntermune Inc Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
JP5554466B2 (ja) 2004-03-01 2014-07-23 味の素株式会社 抗ヒトＴＮＦ−α抗体活性低下抑制剤
ES2456015T3 (es) 2004-03-05 2014-04-21 Dsm Ip Assets B.V. Procedimiento para cultivar células mediante perfusión continua y flujo tangencial alternante
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
ES2432564T3 (es) 2005-05-10 2013-12-04 Biogen Idec Ma Inc. Tratamiento y evaluación de trastornos inflamatorios
JP5068167B2 (ja) 2005-06-10 2012-11-07 中外製薬株式会社 メグルミンを含有するタンパク質製剤の安定化剤、およびその利用
JP2008543839A (ja) * 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
PL1962886T6 (pl) 2005-12-20 2023-03-13 Bristol-Myers Squibb Company Stabilne formulacje białkowe
EP1962907A2 (en) 2005-12-21 2008-09-03 Wyeth a Corporation of the State of Delaware Protein formulations with reduced viscosity and uses thereof
AU2007212147A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
EP2024392A2 (en) 2006-03-17 2009-02-18 Biogen Idec MA, Inc. Stabilized polypeptide compositions
WO2007107340A2 (en) 2006-03-21 2007-09-27 Eugen Oetringer Devices for and methods of analyzing a physiological condition of a physiological subject based on a workload related property
AU2007240732B2 (en) 2006-04-21 2013-07-04 Amgen, Inc. Buffering agents for biopharmaceutical formulations
CN101627117B (zh) * 2006-08-01 2013-10-30 奇尼塔二有限责任公司 医药制造方法
CA2665567C (en) * 2006-10-06 2012-07-03 Amgen Inc. Stable formulations
TW200833357A (en) 2006-10-20 2008-08-16 Amgen Inc Stable polypeptide formulations
JP5401319B2 (ja) 2006-11-03 2014-01-29 ワイス・エルエルシー 細胞培養における解糖阻害物質
WO2008079290A2 (en) 2006-12-21 2008-07-03 Amgen Inc Stable buffered formulations containing polypeptides
ES2541454T3 (es) 2007-03-02 2015-07-20 Wyeth Llc Uso de cobre y glutamato en cultivos celulares para producción de polipéptidos
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
MX2009013593A (es) 2007-06-14 2010-01-20 Biogen Idec Inc Formulaciones de anticuerpos.
CA2904458C (en) 2007-11-30 2017-07-25 Wolfgang Fraunhofer Protein formulations and methods of making same
AU2009204863B2 (en) * 2008-01-15 2015-07-16 AbbVie Deutschland GmbH & Co. KG Powdered protein compositions and methods of making same
JP2011514895A (ja) 2008-02-29 2011-05-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 精製免疫グロブリン融合タンパク質およびその精製方法
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
HRP20200768T4 (hr) 2009-08-11 2025-03-28 F. Hoffmann - La Roche Ag Proizvodnja proteina u mediju za uzgoj stanica bez glutamina
EP2490780A4 (en) 2009-10-20 2014-04-09 Merck Sharp & Dohme USE OF A MIXED MODE CHROMATOGRAPHY FOR THE DETECTION AND PURIFICATION OF BASIC ANTIBODY PRODUCTS
US20130052195A1 (en) 2009-12-23 2013-02-28 Emergent Product Development Seattle,LLC Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof
MX2012012526A (es) 2010-04-26 2012-11-23 Novartis Ag Medio de cultivo celular mejorado.
CN102946858B (zh) * 2010-05-10 2015-09-30 英塔斯制药有限公司 含有免疫球蛋白Fc的多肽的液体制剂
US20130209465A1 (en) 2010-07-30 2013-08-15 Arecor Ltd. Stabilized Aqueous Antibody Compositions
CA2807607A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
WO2012030217A2 (en) 2010-08-31 2012-03-08 Friesland Brands B.V. Culture medium for eukaryotic cells
NZ608943A (en) 2010-10-11 2015-04-24 Abbvie Bahamas Ltd Processes for purification of proteins
EP2699265B1 (en) * 2011-04-20 2019-10-16 Sandoz AG STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
EP2726081A4 (en) 2011-06-29 2015-04-15 Insite Vision Inc METHOD FOR TREATING RECURRING MIBOMEDE DISEASE AND REDUCING THE FREQUENCY FROM THEIR RECURRENCE
PL2726600T3 (pl) 2011-07-01 2017-08-31 Amgen Inc. Hodowla ssaczych komórek
EP2726090B1 (en) 2011-07-01 2020-01-01 Biogen MA Inc. Arginine - free tnfr : fc- fusion polypeptide compositions
US9781540B2 (en) * 2011-07-07 2017-10-03 Qualcomm Incorporated Application relevance determination based on social context
US9556258B2 (en) 2011-07-08 2017-01-31 Merck Sharp & Dohme Corp. Purification of fusion proteins
JP6223338B2 (ja) 2011-08-17 2017-11-01 アレス トレーディング ソシエテ アノニム 活性型ＴＮＦＲ−Ｆｃ融合タンパク質を製造する方法
HK1200718A1 (en) * 2011-10-18 2015-08-14 科荣生生物科学公司 Etanercept formulations stabilized with sodium chloride
PE20150996A1 (es) 2012-09-11 2015-08-01 Coherus Biosciences Inc Etanercept correctamente plegado de alta pureza y excelente rendimiento

Also Published As

Publication number Publication date
KR20140091707A (ko) 2014-07-22
CY1121843T1 (el) 2020-07-31
JP6104922B2 (ja) 2017-03-29
CA2851628A1 (en) 2013-04-25
AR088380A1 (es) 2014-05-28
KR20140079491A (ko) 2014-06-26
LT2768525T (lt) 2019-09-25
US20190290765A1 (en) 2019-09-26
CN104010657A (zh) 2014-08-27
JP2014530256A (ja) 2014-11-17
US20190290767A1 (en) 2019-09-26
US20190298837A1 (en) 2019-10-03
BR112014009131A8 (pt) 2017-06-20
EP2768535A1 (en) 2014-08-27
CA2851639A1 (en) 2013-04-25
HK1200719A1 (en) 2015-08-14
IN2014CN02591A (forum.php) 2015-06-26
CA2851635A1 (en) 2013-04-25
US20180125982A1 (en) 2018-05-10
US9770510B2 (en) 2017-09-26
TW201325610A (zh) 2013-07-01
PL2768525T3 (pl) 2019-10-31
JP2014530863A (ja) 2014-11-20
SG11201401567YA (en) 2014-07-30
IL231824A0 (en) 2014-05-28
TW201325611A (zh) 2013-07-01
SI2768525T1 (sl) 2019-10-30
EA201490802A1 (ru) 2014-08-29
EA026410B1 (ru) 2017-04-28
WO2013059412A1 (en) 2013-04-25
US20160317667A1 (en) 2016-11-03
JP2014530255A (ja) 2014-11-17
CN104011073B (zh) 2017-08-25
SG11201401519RA (en) 2014-07-30
US10980884B2 (en) 2021-04-20
AR088460A1 (es) 2014-06-11
SMT201900422T1 (it) 2019-09-09
US20190184017A1 (en) 2019-06-20
BR112014009073A2 (pt) 2017-05-09
DK2768525T3 (da) 2019-07-22
US10293049B2 (en) 2019-05-21
TWI619504B (zh) 2018-04-01
TW201325607A (zh) 2013-07-01
SG11201401576WA (en) 2014-10-30
US10987405B2 (en) 2021-04-27
KR20140091706A (ko) 2014-07-22
JP2014530862A (ja) 2014-11-20
AU2012326168A1 (en) 2014-04-24
CN104010654B (zh) 2017-10-27
IL231826A0 (en) 2014-05-28
IL231829A0 (en) 2014-05-28
BR112014009087A2 (pt) 2017-04-18
EP2768535A4 (en) 2015-03-11
WO2013059408A1 (en) 2013-04-25
HK1200721A1 (en) 2015-08-14
EP2768533A1 (en) 2014-08-27
JP6199298B2 (ja) 2017-09-20
WO2013059405A1 (en) 2013-04-25
TWI595883B (zh) 2017-08-21
HK1200718A1 (en) 2015-08-14
US20190290766A1 (en) 2019-09-26
EP2768525B1 (en) 2019-06-19
AU2012326082B2 (en) 2016-12-15
BR112014009031A2 (pt) 2017-05-09
CN104010658A (zh) 2014-08-27
US9943601B2 (en) 2018-04-17
US20190314499A1 (en) 2019-10-17
US11129876B2 (en) 2021-09-28
EP2768854A1 (en) 2014-08-27
MX2014004733A (es) 2015-05-15
IL231828A0 (en) 2014-05-28
EP2768525A1 (en) 2014-08-27
HK1200720A1 (en) 2015-08-14
EA025267B1 (ru) 2016-12-30
CN104010654A (zh) 2014-08-27
AU2012326080B2 (en) 2017-02-16
US20180193463A1 (en) 2018-07-12
KR20200008021A (ko) 2020-01-22
BR112014009022A2 (pt) 2017-05-02
CA2851642A1 (en) 2013-04-25
BR112014009146A2 (pt) 2017-06-13
US10772963B2 (en) 2020-09-15
CN103998061A (zh) 2014-08-20
HUE045624T2 (hu) 2020-01-28
AU2012326170A1 (en) 2014-04-24
US20180028668A1 (en) 2018-02-01
WO2013059410A1 (en) 2013-04-25
EA201490803A1 (ru) 2014-09-30
AU2012326171A1 (en) 2014-04-24
US20130101584A1 (en) 2013-04-25
WO2013059407A1 (en) 2013-04-25
US20130108633A1 (en) 2013-05-02
MX2014004726A (es) 2015-05-15
IN2014CN02592A (forum.php) 2015-09-04
CA2851639C (en) 2020-12-29
US10980885B2 (en) 2021-04-20
AU2012326084A1 (en) 2014-04-17
TW201325606A (zh) 2013-07-01
EP2768854A4 (en) 2015-03-11
SG11201401563SA (en) 2014-09-26
EA201490817A1 (ru) 2014-09-30
EA201490804A1 (ru) 2014-09-30
RS59179B1 (sr) 2019-10-31
JP6220788B2 (ja) 2017-10-25
US20190216930A1 (en) 2019-07-18
US9302002B2 (en) 2016-04-05
SG11201401562RA (en) 2014-09-26
AU2012326168B2 (en) 2016-12-15
US10213508B2 (en) 2019-02-26
US20190328875A1 (en) 2019-10-31
EA027325B1 (ru) 2017-07-31
US20190314498A1 (en) 2019-10-17
JP6113176B2 (ja) 2017-04-12
EA201490815A1 (ru) 2014-09-30
KR20140097184A (ko) 2014-08-06
MX2014004732A (es) 2015-05-15
EA028520B1 (ru) 2017-11-30
IN2014CN02527A (forum.php) 2015-06-26
KR20140091705A (ko) 2014-07-22
JP6110393B2 (ja) 2017-04-05
CN103998060B (zh) 2016-12-21
CN103998060A (zh) 2014-08-20
CA2851651A1 (en) 2013-04-25
HK1200722A1 (en) 2015-08-14
US11135267B2 (en) 2021-10-05
EP2768525A4 (en) 2015-07-15
EA025663B1 (ru) 2017-01-30
EP2768531A4 (en) 2015-03-11
EP2768531A1 (en) 2014-08-27
EP2768533A4 (en) 2015-03-11
HK1200851A1 (en) 2015-08-14
MX367054B (es) 2019-08-02
TW201325608A (zh) 2013-07-01
AU2012326084B2 (en) 2016-12-15
ES2734070T3 (es) 2019-12-04
US20130101640A1 (en) 2013-04-25
AU2012326080A1 (en) 2014-04-24
IL231827A0 (en) 2014-05-28
PT2768525T (pt) 2019-07-17
JP2014530254A (ja) 2014-11-17
US9393305B2 (en) 2016-07-19
IL231825A0 (en) 2014-05-28
EP2768532A1 (en) 2014-08-27
BR112014009131A2 (pt) 2017-06-13
AR088379A1 (es) 2014-05-28
KR20140083037A (ko) 2014-07-03
MX2019009176A (es) 2019-10-07
MX2014004728A (es) 2015-05-15
AR088383A1 (es) 2014-05-28
AU2012326170B2 (en) 2016-12-22
CN104011073A (zh) 2014-08-27
CA2851646A1 (en) 2013-04-25
AU2012326171B2 (en) 2017-03-09
SG11201401517VA (en) 2014-09-26
MX2014004725A (es) 2015-02-05
WO2013059406A1 (en) 2013-04-25
JP6220789B2 (ja) 2017-10-25
KR102163150B1 (ko) 2020-10-08
EA201490801A1 (ru) 2014-09-30
US20190314500A1 (en) 2019-10-17
US10376588B2 (en) 2019-08-13
KR102068462B1 (ko) 2020-01-22
TW201325609A (zh) 2013-07-01
TWI644681B (zh) 2018-12-21
US20200405865A1 (en) 2020-12-31
US20130108632A1 (en) 2013-05-02
AU2012326082A1 (en) 2014-04-24
AR088382A1 (es) 2014-05-28
EP2768532A4 (en) 2015-03-11
MX2014004734A (es) 2015-05-15
US10888619B2 (en) 2021-01-12
US20160199489A1 (en) 2016-07-14
US20190290768A1 (en) 2019-09-26
AR088381A1 (es) 2014-05-28
JP2014530864A (ja) 2014-11-20
US9801942B2 (en) 2017-10-31
BR112014009146A8 (pt) 2017-06-20

Similar Documents

Publication Publication Date Title
HRP20191215T1 (hr) Formulacije etanercepta stabilizirane ionima magnezija
JP2016531861A5 (forum.php)
HRP20171296T1 (hr) Derivati benzonitrila kao inhibitori kinaze
JP2016531901A5 (forum.php)
SG11201809746SA (en) Binder based on calcium aluminosilicate derivatives for construction materials.
JP2014012726A5 (forum.php)
ES2571582T3 (es) Composiciones acuosas de aglutinante
JP2011503218A5 (forum.php)
JP2014518276A5 (forum.php)
JP2018538273A5 (forum.php)
SI3142701T1 (en) NEW TREATMENT
HRP20181009T1 (hr) Čestice koje se mogu inhalirati koje sadrže tiotropij
JP2014527040A5 (forum.php)
WO2008129971A1 (ja) 改良された持続感染型センダイウイルスベクター
HRP20170499T1 (hr) Derivati tiazola
JP2015529681A5 (forum.php)
MX2016006330A (es) Composicion farmaceutica que comprende derivados de glutarimida y uso de los mismos en el tratamiento de enfermedades eosinofilicas.
ME02818B (me) Stab ilna tečna formulacija amg 416 (velkalcetida)
UA81563C2 (en) Antagonists of calcitonin gene-related peptide receptors
JP2013500292A5 (forum.php)
RU2016132762A (ru) Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
JP2018530596A5 (forum.php)
JP2018532806A5 (forum.php)
JP2017505809A5 (forum.php)
TW200616967A (en) Novel indazole carboxamides and their use